ANTICANCER THERAPEUTIC VACCINATION USING TELOMERASE-DERIVED UNIVERSAL CANCER PEPTIDES IN METASTATIC NON SMALL CELL LUNG CANCER : A Phase I/II Study

Trial Profile

ANTICANCER THERAPEUTIC VACCINATION USING TELOMERASE-DERIVED UNIVERSAL CANCER PEPTIDES IN METASTATIC NON SMALL CELL LUNG CANCER : A Phase I/II Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs HTERT peptide vaccine-Invectys (Primary) ; Montanide ISA-51
  • Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 05 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 10 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top